TNGX
Tango Therapeutics, Inc.
Price Chart
Latest Quote
$27.64
-2.61 (-8.63%)
Current Price
| Previous Close | $30.25 |
| Open | $29.62 |
| Day High | $29.93 |
| Day Low | $27.13 |
| Volume | 3,743,957 |
Stock Information
| Shares Outstanding | 162.81M |
| Total Debt | $32.79M |
| Cash Equivalents | $379.84M |
| Revenue | $56.99M |
| Net Income | $-107.23M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $4.65B |
| EPS (TTM) | $-0.86 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $3.78B |
| Sales | $56.99M |
| Income | $-107.23M |
| Book/sh | $2.72 |
| Cash/sh | $2.33 |
| Employees | 137 |
Financial Ratios
| Quick Ratio | 26.51 |
| Current Ratio | 27.38 |
| Debt/Eq | 8.38 |
Returns & Margins
| ROA | -20.69% |
| ROE | -38.42% |
| Gross Margin | -126.80% |
| Operating Margin | -206.22% |
| Profit Margin | -188.15% |
Ownership
| Insider Ownership | 1.17% |
| Institutional Ownership | 114.39% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -18.79 |
| P/S | 81.59 |
| P/B | 10.52 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $44.33 |
Technical Indicators
| SMA20 | $29.72 |
| SMA50 | $26.51 |
| SMA200 | $16.48 |
| RSI | 40.68 |
| ATR | 2.0507 |
| Shares Float | 69.56M |
| Short Float | 26.10% |
| Short Ratio | 6.47 |
| Volatility | 1.13 |
| Rel Volume | 0.49 |
Performance History
| Week | -8.05% |
| Month | -11.19% |
| Quarter | +14.06% |
| 6 Months | +130.51% |
| YTD | +219.82% |
| Year | +349.76% |
| 3 Years | +706.78% |
| 5 Years | +161.61% |
| 10 Years | +179.18% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $28.56 | 2,289,100 |
| 2026-07-16 | $27.64 | 3,744,700 |
| 2026-07-15 | $30.25 | 2,278,800 |
| 2026-07-14 | $29.65 | 1,931,300 |
| 2026-07-13 | $28.36 | 2,504,800 |
| 2026-07-10 | $31.06 | 3,372,800 |
| 2026-07-09 | $30.52 | 2,747,000 |
| 2026-07-08 | $30.64 | 3,974,800 |
| 2026-07-07 | $30.12 | 2,795,500 |
| 2026-07-06 | $29.94 | 2,142,400 |
| 2026-07-02 | $29.46 | 2,307,500 |
| 2026-07-01 | $28.73 | 4,361,000 |
| 2026-06-30 | $31.26 | 4,760,900 |
| 2026-06-29 | $32.56 | 5,862,600 |
| 2026-06-26 | $31.47 | 15,371,100 |
| 2026-06-25 | $30.14 | 4,544,000 |
| 2026-06-24 | $29.12 | 4,762,700 |
| 2026-06-23 | $28.39 | 5,387,200 |
| 2026-06-22 | $28.50 | 6,313,500 |
| 2026-06-18 | $27.97 | 12,095,900 |
About Tango Therapeutics, Inc.
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
đ° Latest News
Tango Therapeutics (TNGX) to Benefit From Vopimetostat + KRAS Inhibitors Combined Revenues
Insider Monkey âĸ 2026-07-15T14:01:54Z
2 Monster Growth Stocks Analysts Think Can Reach New Highs
TipRanks âĸ 2026-07-09T17:54:00Z
Tango Therapeutics Rides a New Precision Oncology Trend in 2026
Zacks âĸ 2026-07-02T14:50:00Z
Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?
Zacks âĸ 2026-07-02T14:46:00Z
TNGX Stock Outlook Hinges on Vopimetostat and Key 2026 Catalysts
Zacks âĸ 2026-07-02T14:43:00Z
This Biotech ETF Has Almost Doubled in 13 Months. Money Is Flowing In.
Barrons.com âĸ 2026-06-26T19:38:00Z
Daraxonrasibâs Phase 3 Pancreatic Cancer Survival Data Might Change The Case For Investing In RVMD
Simply Wall St. âĸ 2026-06-12T00:23:37Z
Imviva Unveils Leukemia Data at EHA 2026 With 86% Response Rates
Exec Edge âĸ 2026-06-11T19:56:49Z
Is Tango Therapeutics (TNGX) Price Justified After Its 7x Surge In One Year
Simply Wall St. âĸ 2026-06-10T08:10:37Z
TNGX Stock Jumps 53% on Early Pancreatic Cancer Study Results
Zacks âĸ 2026-06-09T16:44:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $62,384,000 | $42,069,000 | $36,527,000 | $24,860,000 |
| Operating Revenue | $62,384,000 | $42,069,000 | $36,527,000 | $24,860,000 |
| Expenses | ||||
| Total Expenses | $173,673,000 | $187,664,000 | $150,700,000 | $135,931,000 |
| Other Income Expense | $4,069,000 | $7,611,000 | $5,944,000 | $1,493,000 |
| Other Non Operating Income Expenses | $4,069,000 | $7,611,000 | $5,944,000 | $1,493,000 |
| Net Non Operating Interest Income Expense | $5,630,000 | $7,890,000 | $6,619,000 | $1,456,000 |
| Operating Expense | $173,673,000 | $187,664,000 | $150,700,000 | $135,931,000 |
| General And Administrative Expense | $41,508,000 | $43,746,000 | $35,502,000 | $30,025,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-101,594,000 | $-130,302,000 | $-101,744,000 | $-108,176,000 |
| Net Interest Income | $5,630,000 | $7,890,000 | $6,619,000 | $1,456,000 |
| Interest Income | $5,630,000 | $7,890,000 | $6,619,000 | $1,456,000 |
| Normalized Income | $-101,594,000 | $-130,302,000 | $-101,744,000 | $-108,176,000 |
| Net Income From Continuing And Discontinued Operation | $-101,594,000 | $-130,302,000 | $-101,744,000 | $-108,176,000 |
| Total Operating Income As Reported | $-111,289,000 | $-145,595,000 | $-114,173,000 | $-111,071,000 |
| Net Income Common Stockholders | $-101,594,000 | $-130,302,000 | $-101,744,000 | $-108,176,000 |
| Net Income | $-101,594,000 | $-130,302,000 | $-101,744,000 | $-108,176,000 |
| Net Income Including Noncontrolling Interests | $-101,594,000 | $-130,302,000 | $-101,744,000 | $-108,176,000 |
| Net Income Continuous Operations | $-101,594,000 | $-130,302,000 | $-101,744,000 | $-108,176,000 |
| Pretax Income | $-101,590,000 | $-130,094,000 | $-101,610,000 | $-108,122,000 |
| Interest Income Non Operating | $5,630,000 | $7,890,000 | $6,619,000 | $1,456,000 |
| Operating Income | $-111,289,000 | $-145,595,000 | $-114,173,000 | $-111,071,000 |
| Per Share | ||||
| Diluted EPS | $-0.87 | $-1.19 | $-1.08 | $-1.23 |
| Basic EPS | $-0.87 | $-1.19 | $-1.08 | $-1.23 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-109,008,000 | $-143,096,000 | $-111,758,000 | $-109,463,000 |
| Reconciled Depreciation | $2,281,000 | $2,499,000 | $2,415,000 | $1,608,000 |
| EBITDA (Bullshit earnings) | $-109,008,000 | $-143,096,000 | $-111,758,000 | $-109,463,000 |
| EBIT | $-111,289,000 | $-145,595,000 | $-114,173,000 | $-111,071,000 |
| Diluted Average Shares | $116,166,187 | $109,226,731 | $94,572,448 | $87,820,037 |
| Basic Average Shares | $116,166,187 | $109,226,731 | $94,572,448 | $87,820,037 |
| Diluted NI Availto Com Stockholders | $-101,594,000 | $-130,302,000 | $-101,744,000 | $-108,176,000 |
| Tax Provision | $4,000 | $208,000 | $134,000 | $54,000 |
| Research And Development | $132,165,000 | $143,918,000 | $115,198,000 | $105,906,000 |
| Selling General And Administration | $41,508,000 | $43,746,000 | $35,502,000 | $30,025,000 |
| Other Gand A | $41,508,000 | $43,746,000 | $35,502,000 | $30,025,000 |
Fetched: 2026-07-14
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $346,179,000 | $199,517,000 | $253,108,000 | $249,476,000 |
| Total Assets | $398,690,000 | $316,492,000 | $402,567,000 | $436,470,000 |
| Total Non Current Assets | $44,934,000 | $50,149,000 | $56,029,000 | $61,198,000 |
| Other Non Current Assets | $2,442,000 | $2,571,000 | $2,613,000 | $3,428,000 |
| Current Assets | $353,756,000 | $266,343,000 | $346,538,000 | $375,272,000 |
| Other Current Assets | $10,190,000 | $8,426,000 | $8,797,000 | $6,572,000 |
| Restricted Cash | $428,000 | $0 | $856,000 | $567,000 |
| Cash Cash Equivalents And Short Term Investments | $343,138,000 | $257,917,000 | $336,885,000 | $366,133,000 |
| Cash And Cash Equivalents | $112,279,000 | $69,530,000 | $66,385,000 | $59,968,000 |
| Receivables | - | - | $0 | $2,000,000 |
| Accounts Receivable | - | - | $0 | $2,000,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $33,570,000 | $36,493,000 | $38,920,000 | $41,131,000 |
| Long Term Debt And Capital Lease Obligation | $30,832,000 | $34,039,000 | $36,838,000 | $39,361,000 |
| Current Debt And Capital Lease Obligation | $2,738,000 | $2,454,000 | $2,082,000 | $1,770,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $52,511,000 | $116,975,000 | $149,459,000 | $186,994,000 |
| Total Non Current Liabilities Net Minority Interest | $30,832,000 | $78,805,000 | $103,521,000 | $131,449,000 |
| Non Current Deferred Liabilities | $0 | $44,766,000 | $66,683,000 | $92,088,000 |
| Current Liabilities | $21,679,000 | $38,170,000 | $45,938,000 | $55,545,000 |
| Other Current Liabilities | $1,289,000 | $1,735,000 | $1,287,000 | $1,267,000 |
| Current Deferred Liabilities | $0 | $17,618,000 | $25,670,000 | $31,792,000 |
| Payables And Accrued Expenses | $17,652,000 | $16,363,000 | $16,899,000 | $20,716,000 |
| Payables | $1,182,000 | $1,601,000 | $2,785,000 | $4,488,000 |
| Accounts Payable | $1,182,000 | $1,601,000 | $2,785,000 | $4,453,000 |
| Total Tax Payable | - | - | $0 | $35,000 |
| Income Tax Payable | - | - | $0 | $35,000 |
| Equity | ||||
| Common Stock Equity | $346,179,000 | $199,517,000 | $253,108,000 | $249,476,000 |
| Total Equity Gross Minority Interest | $346,179,000 | $199,517,000 | $253,108,000 | $249,476,000 |
| Stockholders Equity | $346,179,000 | $199,517,000 | $253,108,000 | $249,476,000 |
| Gains Losses Not Affecting Retained Earnings | $224,000 | $336,000 | $186,000 | $-3,705,000 |
| Other Equity Adjustments | $224,000 | $336,000 | $186,000 | $-3,705,000 |
| Retained Earnings | $-603,152,000 | $-501,558,000 | $-371,256,000 | $-269,512,000 |
| Preferred Securities Outside Stock Equity | $0 | $0 | $0 | $0 |
| Other | ||||
| Ordinary Shares Number | $135,940,454 | $107,729,343 | $102,202,759 | $88,179,374 |
| Share Issued | $135,940,454 | $107,729,343 | $102,202,759 | $88,179,374 |
| Tangible Book Value | $346,179,000 | $199,517,000 | $253,108,000 | $249,476,000 |
| Invested Capital | $346,179,000 | $199,517,000 | $253,108,000 | $249,476,000 |
| Working Capital | $332,077,000 | $228,173,000 | $300,600,000 | $319,727,000 |
| Capital Lease Obligations | $33,570,000 | $36,493,000 | $38,920,000 | $41,131,000 |
| Total Capitalization | $346,179,000 | $199,517,000 | $253,108,000 | $249,476,000 |
| Additional Paid In Capital | $948,971,000 | $700,631,000 | $624,076,000 | $522,605,000 |
| Capital Stock | $136,000 | $108,000 | $102,000 | $88,000 |
| Common Stock | $136,000 | $108,000 | $102,000 | $88,000 |
| Non Current Deferred Revenue | $0 | $44,766,000 | $66,683,000 | $92,088,000 |
| Long Term Capital Lease Obligation | $30,832,000 | $34,039,000 | $36,838,000 | $39,361,000 |
| Current Deferred Revenue | $0 | $17,618,000 | $25,670,000 | $31,792,000 |
| Current Capital Lease Obligation | $2,738,000 | $2,454,000 | $2,082,000 | $1,770,000 |
| Current Accrued Expenses | $16,470,000 | $14,762,000 | $14,114,000 | $16,228,000 |
| Net PPE | $42,492,000 | $47,578,000 | $53,416,000 | $57,770,000 |
| Accumulated Depreciation | $-10,538,000 | $-8,363,000 | $-5,989,000 | $-3,681,000 |
| Gross PPE | $53,030,000 | $55,941,000 | $59,405,000 | $61,451,000 |
| Leases | $3,723,000 | $2,870,000 | $2,857,000 | $2,778,000 |
| Construction In Progress | $0 | $152,000 | $38,000 | $8,000 |
| Other Properties | $44,560,000 | $48,412,000 | $52,296,000 | $54,606,000 |
| Machinery Furniture Equipment | $4,747,000 | $4,507,000 | $4,214,000 | $4,059,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $230,859,000 | $188,387,000 | $270,500,000 | $306,165,000 |
| Pensionand Other Post Retirement Benefit Plans Current | - | - | - | - |
Fetched: 2026-07-14
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-139,934,000 | $-132,255,000 | $-119,508,000 | $-116,772,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-138,886,000 | $-131,501,000 | $-117,982,000 | $-109,080,000 |
| Cash Flow From Continuing Operating Activities | $-138,886,000 | $-131,501,000 | $-117,982,000 | $-109,080,000 |
| Investing Activities | ||||
| Capital Expenditure | $-1,048,000 | $-754,000 | $-1,526,000 | $-7,692,000 |
| Investing Cash Flow | $-40,865,000 | $86,126,000 | $41,426,000 | $26,399,000 |
| Cash Flow From Continuing Investing Activities | $-40,865,000 | $86,126,000 | $41,426,000 | $26,399,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $212,400,000 | $41,723,000 | $80,017,000 | $0 |
| Financing Cash Flow | $222,500,000 | $47,664,000 | $82,406,000 | $1,615,000 |
| Cash Flow From Continuing Financing Activities | $222,500,000 | $47,664,000 | $82,406,000 | $1,615,000 |
| Net Other Financing Charges | $-36,000 | - | $448,000 | $-8,000 |
| Net Common Stock Issuance | $212,400,000 | $41,723,000 | $80,017,000 | $0 |
| Common Stock Issuance | $212,400,000 | $41,723,000 | $80,017,000 | $0 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| End Cash Position | $114,846,000 | $72,097,000 | $69,808,000 | $63,958,000 |
| Beginning Cash Position | $72,097,000 | $69,808,000 | $63,958,000 | $145,024,000 |
| Changes In Cash | $42,749,000 | $2,289,000 | $5,850,000 | $-81,066,000 |
| Proceeds From Stock Option Exercised | $10,136,000 | $5,941,000 | $1,941,000 | $1,623,000 |
| Net Investment Purchase And Sale | $-39,817,000 | $86,880,000 | $42,952,000 | $34,091,000 |
| Sale Of Investment | $224,640,000 | $327,768,000 | $353,526,000 | $242,595,000 |
| Purchase Of Investment | $-264,457,000 | $-240,888,000 | $-310,574,000 | $-208,504,000 |
| Net PPE Purchase And Sale | $-1,048,000 | $-754,000 | $-1,526,000 | $-7,692,000 |
| Purchase Of PPE | $-1,048,000 | $-754,000 | $-1,526,000 | $-7,692,000 |
| Change In Working Capital | $-67,199,000 | $-31,746,000 | $-37,966,000 | $-18,493,000 |
| Change In Other Working Capital | $-62,384,000 | $-29,969,000 | $-31,527,000 | $-16,860,000 |
| Change In Other Current Liabilities | $-3,032,000 | $-2,140,000 | $-2,439,000 | $1,700,000 |
| Change In Other Current Assets | $-299,000 | $43,000 | $-41,000 | $-10,003,000 |
| Change In Payables And Accrued Expense | $279,000 | $-50,000 | $-3,734,000 | $8,726,000 |
| Change In Accrued Expense | $1,104,000 | $1,134,000 | $-2,029,000 | $7,629,000 |
| Change In Payable | $-825,000 | $-1,184,000 | $-1,705,000 | $1,097,000 |
| Change In Account Payable | $-825,000 | $-1,184,000 | $-1,705,000 | $1,097,000 |
| Change In Prepaid Assets | $-1,763,000 | $370,000 | $-2,225,000 | $-2,056,000 |
| Change In Receivables | $0 | $0 | $2,000,000 | $0 |
| Changes In Account Receivables | $0 | $0 | $2,000,000 | $0 |
| Other Non Cash Items | $3,884,000 | $3,768,000 | $3,628,000 | $1,751,000 |
| Stock Based Compensation | $26,430,000 | $28,897,000 | $19,079,000 | $14,230,000 |
| Amortization Of Securities | $-2,688,000 | $-4,617,000 | $-3,394,000 | $0 |
| Depreciation Amortization Depletion | $2,281,000 | $2,499,000 | $2,415,000 | $1,608,000 |
| Depreciation And Amortization | $2,281,000 | $2,499,000 | $2,415,000 | $1,608,000 |
| Depreciation | $2,281,000 | $2,499,000 | $2,415,000 | $1,608,000 |
| Net Income From Continuing Operations | $-101,594,000 | $-130,302,000 | $-101,744,000 | $-108,176,000 |
| Issuance Of Debt | - | - | - | $0 |
| Net Issuance Payments Of Debt | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |
Fetched: 2026-07-14